Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: A report of eight new cases and literature review

Leukemia and Lymphoma

Volumn 49, Issue 9, 2008, Pages 1762-1768

  Peyrade, Frederic ^a   Triby, Caroline ^a   Slama, Bohane ^b   Fontana, Xavier ^a   Gressin, Remy ^c   Broglia, Jean Marc ^b   Lepeu, GeRard ^b   Carrier, Patricia ^a   Peyrottes, Isabelle ^a   Darcourt, Jacques ^a   Bondiau, Pierre Yves ^a   Thyss, Antoine ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b CENTRE HOSPITALIER D AVIGNON   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Autologous bone marrow transplantation; Follicular lymphoma; Ibritumomab tiuxetan

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXCHLORPHENIRAMINE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; BLOOD TRANSFUSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEASIBILITY STUDY; FOLLICULAR LYMPHOMA; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RELAPSE; RETROSPECTIVE STUDY; SEPTIC SHOCK; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEUTROPENIA; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SHOCK, SEPTIC; THROMBOCYTOPENIA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 52349121694     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802273278     Document Type: Article

References (27)

1. Gallagher, C. J., Gregory, W. M., Jones, A. E., Stansfeld, A. G., Richards, M. A. Dhaliwal, H. S. et al. (1986) Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol, 4, pp. 1470-1510.
2. Liu, Q., Fayad, L., Cabanillas, F., Hagemeister, F. B., Ayers, G. D. Hess, M. et al. (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol, 24, pp. 1582-1589.
3. Deconinck, E., Foussard, C., Milpied, N., Bertrand, P., Michenet, P. Cornillet-LeFebvre, P. et al. (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood, 15, pp. 3817-3823.
4. Freedman, A. S., Gribben, J. G., Neuberg, D., Mauch, P., Soiffer, R. J. Anderson, K. C. et al. (1996) High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood, 88, pp. 2780-2786.
5. Cao, T. M., Horning, S., Negrin, R. S., Hu, W. W., Johnston, L. J. Taylor, T. L. et al. (2001) High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. Biol Blood Marrow Transplant, 7, pp. 294-301.
6. Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P. Haioun, C. et al. (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood, 108, pp. 2540-2544.
7. Brice, P., Simon, D., Bouabdallah, R., Belanger, C., Haioun, C. Thieblemont, C. et al. (2000) High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol, 11, pp. 1585-1590.
8. Schouten, H. C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H. Johnson, H. E. et al. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol, 21, pp. 3918-3927.
9. Brown, J. R., Feng, Y., Gribben, J. G., Neuberg, D., Fisher, D. C. Mauch, P. et al. (2007) Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant, 13, pp. 1057-1065.
10. Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W. Tuck, M. et al. (2000) Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 96, pp. 1259-1266.
11. Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J. Fehrenbacher, L. et al. (2001) Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 19, pp. 3918-3928.
12. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C. Joyce, R. et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 2453-2463.
13. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S. Saleh, M. N. et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 3262-3269.
14. Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, C., Raubitschek, A. Darif, M. et al. (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: Long-term follow-up of a phase I/II study. Blood, 103, pp. 4429-4431.
15. Davies, A. J., Rohatiner, A. Z., Howell, S., Britton, K. E., Owens, S. E. Micallef, I. N. et al. (2004) Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 22, pp. 1469-1479.
16. Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D. Vose, J. M. et al. (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol, 23, pp. 7565-7573.
17. Buchegger, F., Antonescu, C., Delaloye, A. B., Helg, C., Kovacsovics, T. Kosinski, M. et al. (2006) Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer, 94, pp. 1770-1776.
18. Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C., Schilder, R. J. Flinn, I. W. et al. (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90. Cancer, 109, pp. 1804-1810.
19. Hagenbeek, A. and Lewington, V. (2005) Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol, 16, pp. 786-792.
20. Vose, J. M., Bierman, P. J., Loberiza Jr, F. R., Bociek, R. G., Matso, D. and Armitage, J. O. (2007) Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma, 48, pp. 683-690.
21. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L. Horning, S. J. et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol, 25, pp. 579-586.
22. Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W. Zasadny, K. et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 352, pp. 441-449.
23. Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W. Tuck, M. et al. (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood, 96, pp. 1259-1266.
24. Jacobs, S. A., Vidnovic, N., Joyce, J., McCook, B., Torok, F. and Avril, N. (2005) Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res, 11, pp. 7146s-7150s.
25. Peyrade, F., Italiano, A., Fontana, X., Peyrottes, I. and Thyss, A. (2007) Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment. Lancet Oncol, 8, pp. 849-850.
26. Czuczman, M. S., Emmanouilides, C., Darif, M., Witzig, T. E., Gordon, L. I. Revell, S. et al. (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol, 25, pp. 4285-4292.
27. Zinzani, P. L., Tani, M., Fanti, S., Stefoni, V., Musuraca, G. Vitolo, U. et al. (2008) A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by 90Y-labelled ibritumomab tiuxetan for patients with previously untreated indolent, nonfollicular, non-Hodgkin Lymphoma. Cancer, 112, pp. 856-862.